Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health...

Full description

Bibliographic Details
Main Authors: Mario Schiavoni, Mariasanta Napolitano, Gaetano Giuffrida, Antonella Coluccia, Sergio Siragusa, Valeria Calafiore, Giuseppe Lassandro, Paola Giordano
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Medicine
Subjects:
Hemophilia A
recombinant Factor VIII products
pharmacokinetics
inhibitors
EHL-rFVIII
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2019.00261/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2019.00261/full

Similar Items